Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
eFFECTOR Therapeutics (EFTR)
NASDAQ:EFTR
RESEARCH TOOLSreports
eFFECTOR Therapeutics (EFTR) Stock Price & Analysis
238 Followers
EFTR Stock Chart & Stats
Day’s Range$2.08 - $2.26
52-Week Range― - ―
Previous Close$2.2
Volume108.69K
Average Volume (3M)N/A
Market Cap
$10.35M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 07, 2024EPS Estimate
-$2.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.00Price Target Upside409.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
eFFECTOR Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentZotatifin could significantly impact treatment paradigms in attractive commercial niches within oncology.
Financial HealthEFFECTOR Therapeutics reported financial results in line with estimates and possesses sufficient financial resources to provide an operational runway into 1Q25.
Stock ValuationAnalyst reiterates a Buy rating with a 12-month price target of $24 per share, indicating a potential upside for the stock.
Bears Say
Drug DevelopmentFurther development of tomivosertib in NSCLC is discontinued after primary endpoint miss.
Financial ForecastRevenue projections for tomivosertib have been removed from the valuation.
Stock PerformanceThe company’s stock went down significantly due to the trial results.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EFTR FAQ
What was eFFECTOR Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is eFFECTOR Therapeutics’s market cap?
Currently, no data Available
When is eFFECTOR Therapeutics’s upcoming earnings report date?
eFFECTOR Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 4 days.
How were eFFECTOR Therapeutics’s earnings last quarter?
eFFECTOR Therapeutics released its earnings results on Mar 25, 2024. The company reported -$3.42 earnings per share for the quarter, missing the consensus estimate of -$2.82 by -$0.6.
Is eFFECTOR Therapeutics overvalued?
According to Wall Street analysts eFFECTOR Therapeutics’s price is currently Undervalued.
Does eFFECTOR Therapeutics pay dividends?
eFFECTOR Therapeutics does not currently pay dividends.
What is eFFECTOR Therapeutics’s EPS estimate?
eFFECTOR Therapeutics’s EPS estimate is -$2.17.
How many shares outstanding does eFFECTOR Therapeutics have?
Currently, no data Available
What happened to eFFECTOR Therapeutics’s price movement after its last earnings report?
eFFECTOR Therapeutics reported an EPS of -$3.42 in its last earnings report, missing expectations of -$2.82. Following the earnings report the stock price went down -6.177%.
Which hedge fund is a major shareholder of eFFECTOR Therapeutics?
Among the largest hedge funds holding eFFECTOR Therapeutics’s share is Blackstone Inc.. It holds eFFECTOR Therapeutics’s shares valued at 611K.
---
eFFECTOR Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (409.26% Upside)
$11.00 (409.26% Upside)
Blogger Sentiment
Bullish
EFTR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 32.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.35%
Trailing 12-Months
Company Description
eFFECTOR Therapeutics
Locust Walk Acquisition Corp is a blank check company.
---
EFTR Stock 12 Months Forecast
Average Price Target
$11.00
▲(409.26% Upside)
Technical Analysis
Best Analysts Covering EFTR
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-58.16%
reiterated a buy rating 11 months ago
Copying Judah Frommer's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -58.16% per trade.
---